A Phase 2, randomized, double-blind, placebo-controlled, parallel group, 3-arm, multinational, multicenter, proof-of-concept study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in adult participants with severe alopecia areata

To be considered for this study, you must be an adult, aged 18 or older. Both men and women are welcome to take part in this research.

The study is specifically looking for people with severe alopecia areata. This means your hair loss must be significant, affecting a large portion of your scalp. The medical team will use a special scoring system to check if your hair loss meets the study's requirements.

There might be other health conditions or medicines that would prevent you from joining, to ensure your safety. The study team will review your full medical history to see if this study is right for you.

If you decide to join this study, you will be in the study for about 36 weeks, which is roughly 8 to 9 months, plus follow-up visits. You would receive either the study medicine (amlitelimab) or a placebo, given as injections under the skin. You, and your study doctor, would not know which one you are receiving.

Over the course of the study, you would attend regular appointments at the study clinic. These visits would involve several assessments. Doctors and nurses would check your hair growth, especially on your scalp, eyebrows, and eyelashes, using special measurements. They would also ask you questions about how you feel and your quality of life. Additionally, you would have blood tests and other health checks to monitor your safety and how your body is reacting to the treatment. The research team will explain all the details of these visits before you agree to participate.